louisiana glp-1 gastrointestinal obstruction class action Chynthia Bromley | The Farmacy | Over 2,000 lawsuits have now been filed against Ozempic's manufacturer, Novo Nordisk, alleging that the company failed to adequately warn glp-1 gastric intestinal obstruction class
Description
Diabetologia 67 , 459469 (2024)
It has been proposed that GLP-1 may contribute to the exaggerated insulin surge and resultant hypoglycemia
Both work similarly to control appetite and support gradual weight loss
The physiological profile of METRNL is nevertheless highly attractive
Overall, the findings from these two recently completed cardiovascular outcomes trials suggest that the increases in HR associated with the short-acting GLP-1 RA, lixisenatide, or the long-acting GLP-1 RA, liraglutide, do not lead to an increased risk of major adverse cardiac events in patients with T2DM and high cardiovascular risk
